Our team members Sante Leandro Baldi and Clara Fappani represented MACH at EUROGIN, the international multidisciplinary HPV congress in Porto, Portugal.
The event, hosted at Alfândega Congress Center in Porto, is dedicated to advancing scientific efforts in the prevention and control of HPV-related cancers.
Every year, EUROGIN gathers global experts to share the latest advancements, strategies, and insights aimed at reducing the burden of cervical cancer and other HPV-associated conditions worldwide.
MACH team presented three innovative studies from our HPV implementation research project at St. Philips Clinic, Eswatini.
Implementation of urine-based HR-HPV testing for cervical cancer prevention in rural Eswatini
In our general study we introduced a urine-based HPV screening method in rural Eswatini, successfully increasing accessibility and acceptability, especially among younger women. The project identified a high prevalence of high-risk HPV types and emphasized the importance of tailored interventions.
Claiming choices: increasing acceptability of cervical cancer screening among women and girls in rural Eswatini
Our mixed-method acceptability study revealed that urine-based HPV screening significantly reduced barriers like social stigma and discomfort associated with traditional screenings, highlighting community sport and advocacy as crucial elements for increased participation.
Human papilloma virus genotypes distribution among women screened for cervical cancer in a rural healthcare facility in Eswatini
In our epidemiology study we analyzed HPV genotypes from urine samples, finding a high prevalence of multiple high-risk HPV types, notably HPV35, underscoring the need for targeted prevention strategies and informed vaccine policies in Eswatini.
These studies represent a significant step toward improving cervical cancer elimination and control strategies globally, particularly in underserved rural areas.